selectION INC., based in San Diego, California, has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Its most advanced drug candidate is si-544, a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases. The Company is well positioned to expand its range of class leading ion channel blockers by targeting additional potassium, sodium, calcium and chloride channel, which will lead to other clinical applications in pain management and oncology.